WaveMan
WaveMan · Company
SPRY · Ars Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SPRY ARS Pharmaceuticals (SPRY) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001671858
Quote by TradingView
Form 144 · 16
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
113
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $37.5K priced

What the filings say about SPRY

Insiders, 180 days
-$283.6K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$4.1M
16 notices

ARS Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ARS Pharmaceuticals, Inc. insiders sold a net $283.6K of stock across 210 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Karas Eric
Chief Commercial Officer
SELL
2026-06-12 SEC
25,000
$250.0K
-60.0%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jul 1, 2025.
  • The trade is 205.3% of the 12,176 shares held after it.
  • 1 other insider sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Karas Eric sold about $250.0K of SPRY on Jun 12, 2026; 1 other insider sold within 30 days and 113 funds added in the latest 13F quarter.
Fitzpatrick Alexander A
Chief Legal Officer
SELL
2026-06-12 SEC
3,355
$33.5K
-60.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on May 20, 2025.
  • +51.7% median (+51.7% mean) 90-day return after 2 previous buys.
  • The trade is 3.7% of the 90,910 shares held after it.
  • 1 other insider sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Fitzpatrick Alexander A sold about $33.5K of SPRY on Jun 12, 2026; 1 other insider sold within 30 days and 113 funds added in the latest 13F quarter.
Dorsey Brian
Chief Operating Officer
SELL
2025-11-14 SECtraded 2025-11-13
21,828
$190.1K
-46.4%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Dec 12, 2024.
  • The trade is 202.3% of the 10,789 shares held after it.
  • 1 other insider sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Dorsey Brian sold about $190.1K of SPRY on Nov 13, 2025; 1 other insider sold within 30 days and 113 funds added in the latest 13F quarter.
Chakma Justin
Chief Business Officer
SELL
2025-11-14 SECtraded 2025-11-12
136,380
$1.2M
-46.4%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Dec 13, 2024.
  • 1 other insider sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Chakma Justin sold about $1.2M of SPRY on Nov 12, 2025; 1 other insider sold within 30 days and 113 funds added in the latest 13F quarter.
Chakma Justin
Chief Business Officer
SELL
2025-11-14 SECtraded 2025-11-12
30,000
$267.3K
-46.4%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Dec 13, 2024.
  • The trade is 22.0% of the 136,380 shares held after it.
  • 1 other insider sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Chakma Justin sold about $267.3K of SPRY on Nov 12, 2025; 1 other insider sold within 30 days and 113 funds added in the latest 13F quarter.
210 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 205 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$283.6K over 180 days
more than 50% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
113 funds bought in last quarter
more than 73% of Pharma & Biotech
Revenue
-5.5% year over year
below 62% of Pharma & Biotech
Margin
-203.3% net margin
below 66% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
44.1% of the float short (float per yahoo 2026-10-26) · 16.1 days to cover · settled 2026-09-30
more than 95% of Pharma & Biotech
What changed in the last 30 days
Oct 19Officer ERIC KARAS filed to sell $410.2K by Oct 19 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Officer ERIC KARAS filed to sell $426.1K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Sep 30Officer ERIC KARAS filed to sell $431.6K by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch SPRY

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-59.4%12M
-59%-28%+4%+35%2025-102025-122026-022026-042026-062026-082026-10 2025-11-12 · Chakma Justin sold $1.2M2025-11-12 · Chakma Justin sold $267.3K2026-06-12 · Karas Eric sold $250.0K2025-11-13 · Dorsey Brian sold $190.1K2026-06-12 · Fitzpatrick Alexander A sold $33.5K2026-10-19 · ERIC KARAS filed to sell $410.2K2026-10-01 · ERIC KARAS filed to sell $426.1K2026-09-30 · ERIC KARAS filed to sell $431.6K2026-09-11 · ERIC KARAS filed to sell $69.8K2026-09-11 · RICHARD LOWENTHAL filed to sell $177.0K2026-09-04 · RICHARD LOWENTHAL filed to sell $421.1K2026-09-03 · RICHARD LOWENTHAL filed to sell $115.6K2026-09-02 · RICHARD LOWENTHAL filed to sell $5.0K2026-09-01 · SARINA TANIMOTO filed to sell $272.8K2026-08-31 · SARINA TANIMOTO filed to sell $368.1K2026-08-20 · RICHARD LOWENTHAL filed to sell $148.2K2026-08-20 · SARINA TANIMOTO filed to sell $148.0K2026-08-19 · RICHARD LOWENTHAL filed to sell $322.3K2026-08-19 · SARINA TANIMOTO filed to sell $161.2K2026-08-18 · RICHARD LOWENTHAL filed to sell $315.9K2026-08-18 · SARINA TANIMOTO filed to sell $311.2K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SPRY: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
10,860,977 sh
$87.0M
Rubric Capital Management LP
8,540,861 sh
$68.4M
ORBIMED ADVISORS LLC
8,288,510 sh
$66.4M
DEERFIELD MANAGEMENT COMPANY, L.P.
7,503,812 sh
$60.1M
BlackRock, Inc.
5,311,319 sh
$42.5M

Congress trades in SPRY

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SPRY planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
ERIC KARAS
Filed 2026-10-19
$410.2K
ERIC KARAS
Filed 2026-10-01
$426.1K
ERIC KARAS
Filed 2026-09-30
$431.6K
ERIC KARAS
Filed 2026-09-11
$69.8K
RICHARD LOWENTHAL
Filed 2026-09-11
$177.0K

SPRY mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$928.3K position · as of 2026-05-31
0.6%
Sit Small Cap Growth Fund
$585.5K position · as of 2026-06-30
0.4%
Empower Small Cap Growth Fund
$877.3K position · as of 2026-06-30
0.3%
Optimum Small-Mid Cap Growth Fund
$1.8M position · as of 2026-06-30
0.2%
Royce Smaller-Companies Growth Fund
$432.5K position · as of 2026-06-30
0.2%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$18.3M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 2
1 active
1
Phase 4
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$9.7M
$10.2M
$4.1M
+113%
n/a
2024
$7.2M
$14.6M
$3.2M
+93%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $283.6K sold by insiders over 180 days, 113 funds added last quarter, $4.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SPRY financials

Revenue growth
-5.5%
XBRL, annual
Net margin
-203.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$116.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-184.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$196.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
7.73x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-2.03x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-210.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-76.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-94.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$478.3M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-50.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$84.3M$89.1M$30.0K$1.3M
Operating income-$179.4M-$3.1M-$67.5M-$35.5M
Net income-$171.3M$8.0M-$54.4M-$34.7M
EPS (diluted)-1.740.08-0.57-0.87
Operating cash flow-$170.9M$13.5M-$59.3M-$40.1M
Cash$41.3M$50.8M$71.0M$210.5M
Long-term debt$96.4M$0n/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

SPRY Stock Sonar score 6/7 axes

Find similar shapesCompare

SPRY ranks highest on institutional and government (73rd percentile) and growth (38th), and lowest on risk and compliance (13th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
25
Inputs
  • Return on equity-210.3% · 16 pct, sector of 545
  • Return on assets-76.5% · 31 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-94.7% · 27 pct, sector of 576
Financial health
23
Inputs
  • Debt to equity7.73x · 3 pct, sector of 352
  • Cash flow to debt-2.03x · 44 pct, sector of 371
Growth
38
Inputs
  • Revenue growth, YoY-5.5% · 38 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
24
Inputs
  • Net Form 4 buying (codes P and S), 180d-$284K · 47 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
73
Inputs
  • Funds adding, latest quarter113 · 73 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
13
Inputs
  • Short interest, % of float+44.1% · 1 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+16.4% · 26 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SPRY filings, in plain words

Are ARS Pharmaceuticals insiders buying or selling SPRY?

In the 180 days to 2026-10-28, ARS Pharmaceuticals insiders were net sellers, a net $283.6K across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of SPRY?

Yes. 16 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $4.1M of stock; the latest, by ERIC KARAS, was filed 2026-10-19.

Read the full summary

In the 180 days to 2026-10-28, ARS Pharmaceuticals insiders were net sellers of SPRY, a net $283.6K across purchases and sales reported on Form 4 by 2 sellers. Insiders filed 16 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $4.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies